New AD Derm drug

Quote
Decisions being discussed over coming weeks about what to do with the derm business unit. Fold into Rheum and have combined force and retain only the best in a given market, reduce the teams further, or dissolve the products and give Cibinqo to Rheum and Eucrisa to PCP? Eucrisa volume is a fraction of what it was 4 years ago, and Cibinqo has next to no volume nationally. Still to much headcount across the board even though many have left for other jobs and other divisions within Pfizer and externally. This is an easy job, no pressure, high salaries, great benefits-may as well ride this out till a package arrives. No guarantees to land back in derm as some may view us as tarnished now due to not being performance driven, but many others don't or won't know the culture here. Why would you leave now knowing a package is around the corner potentially?
 




anonymous said:
Decisions being discussed over coming weeks about what to do with the derm business unit. Fold into Rheum and have combined force and retain only the best in a given market, reduce the teams further, or dissolve the products and give Cibinqo to Rheum and Eucrisa to PCP? Eucrisa volume is a fraction of what it was 4 years ago, and Cibinqo has next to no volume nationally. Still to much headcount across the board even though many have left for other jobs and other divisions within Pfizer and externally. This is an easy job, no pressure, high salaries, great benefits-may as well ride this out till a package arrives. No guarantees to land back in derm as some may view us as tarnished now due to not being performance driven, but many others don't or won't know the culture here. Why would you leave now knowing a package is around the corner potentially?
Click to expand...

I would leave in a heartbeat. There is no guarantee you find a better job so if one opened I'm gone.
 












anonymous said:
Decisions being discussed over coming weeks about what to do with the derm business unit. Fold into Rheum and have combined force and retain only the best in a given market, reduce the teams further, or dissolve the products and give Cibinqo to Rheum and Eucrisa to PCP? Eucrisa volume is a fraction of what it was 4 years ago, and Cibinqo has next to no volume nationally. Still to much headcount across the board even though many have left for other jobs and other divisions within Pfizer and externally. This is an easy job, no pressure, high salaries, great benefits-may as well ride this out till a package arrives. No guarantees to land back in derm as some may view us as tarnished now due to not being performance driven, but many others don't or won't know the culture here. Why would you leave now knowing a package is around the corner potentially?
Click to expand...

Ummmm hello?? Duh! This has already been decided. Derm is folding into PCP and rheum is taking over all JAKS since that is where JAKS started. This is happening 9/1.
 












All the other companies have Jaks and Tyks in their pipeline of launching soon. They are here to stay and the safety profile will the same. The HCPs are going to have to get comfortable with them like they had to with the psoriasis meds. Eventually they will.
 








anonymous said:
All the other companies have Jaks and Tyks in their pipeline of launching soon. They are here to stay and the safety profile will the same. The HCPs are going to have to get comfortable with them like they had to with the psoriasis meds. Eventually they will.
Click to expand...
Have you talked to your doctors? Mine say the problem isn’t their comfort level, it’s patient refusing to try the new JAK class. In AA, a much smaller pat pop btw, the pats won’t care (if they’re not already on Olumiant) but in AD too many pats feel like there are safer options with same efficacy.
What’s the best medicine doc? The ones patients take. That is our fight. And it’s going to take years, just like the psoriasis drugs took. So, hopefully Pfizer sticks with it but I’m not super confident they’ll keep hemorrhaging $$$ when another division (RD) under our umbrella is selling 10x our sales with half the sales force.
 




anonymous said:
All the other companies have Jaks and Tyks in their pipeline of launching soon. They are here to stay and the safety profile will the same. The HCPs are going to have to get comfortable with them like they had to with the psoriasis meds. Eventually they will.
Click to expand...
The market ( Drs and patients) will determine whether they succeed or not, not companies coming out with more unless it can be proven safer.
 




anonymous said:
All the other companies have Jaks and Tyks in their pipeline of launching soon. They are here to stay and the safety profile will the same. The HCPs are going to have to get comfortable with them like they had to with the psoriasis meds. Eventually they will.
Click to expand...

Sorry Mr. or Ms. Wizard...HCP's won't as long as they have Dupixent. Just ask yourself, if HCP's had a 'just as effective' PsO biologic option but without all of the warnings, what do you think they'd do?

Oh by the way, indicated for multiple atopic conditions & with AD, down to 6 mos. Drop mic
 




Good points, especially convincing pts. I was surprised by the number of HCPs that had AEs w biologics and tachyphylaxis over time. Was also surprised by the compliance issues. Once you say it’s a pill, they always say that’s a lot easier to deal with than shots.
 




The above poster is absolutely correct. Patients are saying no and changing their minds. Are providers not discussing the product with them enough? Most providers are in and out of the rooms, not really discsussing safety profile. Then patient goes home and googles the product...game over...it's all JAKs not just ours.
 




























Top Bottom
Back
Quote